Stocks Surge On Moderna Vaccine News Redux Tyler Durden Tue, 07/14/2020 - 17:09 US equity markets are higher after-hours following news that Moderna’s potential COVID-19 vaccine produced immune responses in patients in the early stage trial, according to results published in a peer-reviewed journal for the first time. The US biotech company’s vaccine candidate produced antibodies in all 45 participants in the first cohort of the phase one trial run by the National Institutes of Health, while the paper said there were no safety problems that could curtail further trials. On May 18th we were told the headlines on this trial (on 8 patients)... this is the details of that study on the full 45 patients CONCLUSIONS The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. As The FT reports, Tal Zaks, chief medical officer at Moderna, said the vaccine candidate — known as mRNA-1273 — elicits a “robust immune response across all dose levels”. “We look forward to beginning our Phase three study of mRNA-1273 this month to demonstrate our vaccine’s ability to significantly reduce the risk of Covid-19 disease,” he said. The broad market is spiking on this old news... MRNA is also soaring... Which we humbly suggest will be an insider-selling opportunity Remember what happened last time!